Dosing & Uses
Dosage Forms & Strengths
cream/lotion/ointment
- 0.1%
Inflammatory Hyperkeratotic Dermatosis
Apply cream, lotion or ointment to affected area qDay
Administration
Do not use with occlusive dressings
Other Indications & Uses
Dermatosis-associated inflammation and pruritus
Potency: Medium
Dosage Forms & Strengths
cream/lotion/ointment
- 0.1%
Inflammatory Hyperkeratotic Dermatosis
<2 years: Safety and efficacy not established
2 years or older: As adults: apply cream, lotion or ointment to affected area qDay
Use beyond 3 weeks not studied
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
Frequency Not Defined
Burning
Itching
Pruritus
Rosacea
Postmarketing Reports
Irritation
Dryness
Folliculitis
Hypertrichosis
Acneiform eruptions
Hypopigmentation
Perioral dermatitis
Allergic contact dermatitis
Secondary infection
Skin atrophy
Striae
Miliaria
Blurred vision
Cataracts
Glaucoma
Increased intraocular pressure
Central serous chorioretinopathy
Warnings
Contraindications
Hypersensitivity
Cautions
Safety/efficacy in children use for longer than 3 wk not established; pediatric patients may be more susceptible to systemic toxicity
Reversible HPA axis suppression with potential for glucocorticosteroid insufficiency after withdrawal of treatment; Cushing’s syndrome, and hyperglycemia may occur due to systemic absorption; patients applying topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression; modify use should HPA axis suppression develop
Do not use with occlusive dressings
Not for acne, rosacea, perioral dermatitis, diaper dermatitis
Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma
Avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation
Pregnancy & Lactation
Pregnancy Category: C
Lactation: use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Absorption: 0.4%
Metabolism: hepatic P450 enzyme CYP3A4
Excretion: N/A
Potency
Medium
Relative potency: ointment >cream >lotion >solution
Very-high: clobetasol, diflorasone diacetate ointment 0.05%, halobetasol
High: betamethasone dipropionate 0.05%, amcinonide, fluocinonide, desoximetasone, mometasone, diflorasone emollient 0.05%, halcinonide
Medium: triamcinolone, betamethasone valerate 0.1%, fluticasone, flurandrenolide, fluocinolone 0.025%, hydrocortisone
Mild: hydrocortisone 0.5, 1, 2.5% base, desonide, alclometasone
Mechanism of Action
Anti-inflammatory corticosteroid
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
